CNSide CLEARING THE WAY

FOR THE DIAGNOSIS AND MANAGEMENT OF BRAIN METASTASES IN PATIENTS WITH BREAST AND LUNG CANCER

The CNSide[™] assay is not an FDA cleared or approved assay. It is a Biocept lab developed test and its performance characteristics were determined in Biocept's CLIA-certified, CAP-approved laboratory.



TO MEET THE CHALLENGE OF DIAGNOSING AND TREATING METASTATIC BRAIN TUMORS

ASK THE QUESTION: IS THERE A TUMOR? IS THERE A TREATMENT? IS THERE A TREND?



Now there's a better way to know.



A NEW ASSAY. A BETTER ANSWER.

Introducing CNSide[™]

A diagnostic assay providing answers to questions current diagnostic tests cannot reliably address:

Is there a tumor?

CNSide can detect and quantify tumor cells in cerebrospinal fluid in patients with breast or lung cancer and suspected brain metastasis

Is there a treatment?

CNSide can identify actionable targets for treatment

Is there a trend?

CNSide can monitor tumor cell count, response to therapy and disease progression



A SIGNIFICANT ADVANCE VS. CSF CYTOLOGY AND IMAGING

CNSide[™] is a novel combination of cell-based and cell-free assays utilizing proprietary assay technology

- · CNSide is quantitative, while cytology and imaging are qualitative
- CNSide is more sensitive and can detect a higher percentage of tumor cells than cytology¹
- CNSide detected tumor cells in approximately 80% of cases with suspected disease in one study compared with approximately 50% of cases examined by CSF cytology¹



CASE STUDY REAL-WORLD ANSWERS TO QUESTIONS

BACKGROUND

- 41-year-old female patient with a history of breast cancer presented with neurological symptoms—headache, double vision and seizures
- · Imaging suggested signs of brain metastases
- CSF cytology was indeterminate
- Oncologist ordered CNSide[™]

CNSide RESULTS


- >25,000 CSF tumor cells detected
- Biomarker analysis positive for HER2 (negative in primary tumor)

DECISION IMPACT

- · Patient started on intrathecal trastuzumab
- · Repeated testing demonstrated a significant and sustained decrease in CSF tumor cell count



CASE STUDY IS THERE A TUMOR? YES. IS THERE A TREATMENT? YES. IS THERE A TREND? YES.



CNSide Collection Dates

Approximately 50% of brain metastases have actionable mutations not detected in the primary tumor²

The identification of CSF tumor cells and an actionable biomarker gave the physician and patient confidence. The tumor responded to treatment and the patient resumed an active life.



IS THERE A TUMOR? IS THERE A TREATMENT? IS THERE A TREND?

WHEN YOU NEED AN ANSWER TO YOUR QUESTIONS INVOLVING BRAIN METASTASES, THERE IS NO SUBSTITUTE FOR THE CNSide ASSAY.









Clearing the way to better outcomes.

f У in

Biocept, Inc. 9955 Mesa Rim Road San Diego, CA 92121

© 2021 Biocept, Inc. All rights reserved. CNSide is a trademark of Biocept, Inc.

MKTG-0096.01 www.Biocept.com

Biocept